Rating Change
Chardan Capital reiterated its Buy rating on Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) on October 23, 2026.
reiterateNASDAQ:OBIO
Chardan Capital Reiterates Buy Rating on Orchestra BioMed Holdings, Inc. (OBIO)
Chardan Capital reiterated its Buy rating on Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) on October 23, 2026.
At publication ·
What changed
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) · reiterate
- Firm
- Chardan Capital
- Rating
- Buy to Buy
- Price at event
- $5.59
- Market capitalization
- $257.8M
At a glance
Key takeaways
- Chardan Capital reiterated a Buy rating on Orchestra BioMed Holdings (OBIO) on October 23, 2026.
Market Context
Orchestra BioMed Holdings, Inc. operates in the Healthcare sector. The stock currently trades at $5.59 with a market capitalization of $257.8M. The stock has gained 48.9% over the past 52 weeks.
Analyst coverage from Chardan Capital provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Orchestra BioMed Holdings, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Orchestra BioMed Holdings, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 23, 2026 | Chardan Capital | Buy | N/A |
| Sep 15, 2026 | B. Riley Securities | Buy | N/A |
| Sep 10, 2026 | BTIG | Buy | N/A |
| Aug 11, 2026 | Piper Sandler | Overweight | N/A |
| May 19, 2026 | B. Riley Securities | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View OBIO Stock Page
Frequently Asked Questions
What does the Buy rating mean for OBIO?
A rating of Buy from Chardan Capital reflects the analyst's outlook on Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the OBIO forecast page.